Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Riley Hospital for Children at Indiana University Health
Cancer & Blood Diseases11700 N Meridian St
Carmel, Indiana, United States
Phone Web
The Cancer & Blood Diseases Department at Riley at IU Health works hand-in-hand with a large team of doctors and support staff from a variety of specialties to provide every possible treatment option available. The child’s care plan may involve a treatment or therapy that is provided by specialists from the following Riley at IU Health departments:
– Integrative Medicine & Palliative Care
– Neurology
– Neurosurgery
– Pain Management
– Physical Therapy & Rehabilitation
– Radiology & Imaging
The health team at Riley at IU Health cares about the child, and they also care about future children who will be affected by cancer and blood diseases. That is why the physician-scientists at Riley at IU Health and Indiana University Health University Hospital focus on research and clinical trials.
The IU Health Melvin and Bren Simon Cancer Center is the only National Cancer Institute (NCI)-designated cancer center for clinical care in Indiana. It provides the only pediatric stem cell (bone marrow) transplant program in the state and is member of the Children’s Oncology Group Phase I & Pilot Consortium. This means it receives early access to clinical trials and newly developed cancer treatments and research.
+myBinderRelated Content
-
Mandy DavidMandy David is a senior health communica...
-
Impact of emergency department care on outcomes of acute pain events in children with sickle cell diseaseThe impact of emergency department (ED) ...
-
Family functioning, medical self-management, and health outcomes among school-aged children with sickle cell disease...BACKGROUND: Informed by the Pediatric S...
-
Yogen Saunthararajah, MDYogen Saunthararajah, MD, is a staff in ...
-
The Sickle Cell Care Coordination InitiativeThe Sickle Cell Care Coordination Initia...
-
Doris Duke Charitable Foundation awards grant to Critical Path InstituteIn a continuing effort to spur advance...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
